HAWTHORNE, N.Y., Sep 23, 2003 /PRNewswire via COMTEX/ -- Get ready for the biggest innovation in children's products since disposable diapers! Just in time for back-to-school runny noses and cold and flu season, Taro Pharmaceuticals introduces ElixSure(TM), a line of spill-resistant single-symptom
HAWTHORNE, N. Y.--(BUSINESS WIRE)--July 24, 2003-- 30th Consecutive Quarter of Record Sales; 20th Consecutive Quarter of Record Net Income Second Quarter 2003 Highlights: -- Sales Increase 51% to $74.8 Million -- Gross Profit Increases 62% to $50.0 Million -- Net Income Increases 45% to $14.8
HAWTHORNE, N.Y.--(BUSINESS WIRE)--July 10, 2003--Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) intends to report financial results for the second quarter of 2003 prior to the Nasdaq market opening on Thursday, July 24, 2003. The Company will conduct a conference call to discuss the results
HAWTHORNE, N.Y., Jun 23, 2003 (BUSINESS WIRE) -- Taro Pharmaceuticals U.S.A., Inc., the U.S. affiliate of Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO), today announced plans for the August 2003 launch of a line of OTC cough and cold products based on the Company's patented NonSpil(TM) liquid
HAWTHORNE, N.Y., Jun 2, 2003 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS:TARO) today announced the completion of its previously announced offering of $60 million in long-term, non-convertible debt to certain banks and institutional investors in Israel.
HAWTHORNE, N.Y.--(BUSINESS WIRE)--May 22, 2003--Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS:TARO) today announced that the Company intends to offer up to $60 million in long-term, non-convertible debt solely to Israeli banks and institutional investors in Israel.
HAWTHORNE, N.Y., Apr 16, 2003 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO): First Quarter Highlights -- Sales Increase 55% to $69.0 Million -- Net Income Increases 42% to $14.0 Million, or $0.47 per Diluted Share -- Etodolac Extended-Release Tablets ANDA Approved in the
HAWTHORNE, N.Y., Apr 11, 2003 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) intends to report financial results for the first quarter of 2003 prior to the Nasdaq market opening on Wednesday, April 16, 2003. The Company will conduct a conference call to discuss the results on
HAWTHORNE, N.Y.--(BUSINESS WIRE)--April 10, 2003--Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for ammonium lactate cream, 12%.
HAWTHORNE, N.Y.--(BUSINESS WIRE)--March 31, 2003--Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS:TARO) today announced that it has received an "AA" rating from Maalot, the Israeli affiliate of Standard & Poor's, based on the rating standard employed in Israel, for the issuance of debt securities
Alerts are e-mailed to you whenever certain new company information is posted to this site.
